Aethlon Medical Q3 operating expenses up 13.6% yr/yr

Reuters02-13
Aethlon Medical Q3 operating expenses up 13.6% yr/yr

Overview

  • Medical therapeutic firm's fiscal Q3 operating expenses rose 13.6% yr/yr

  • Operating expenses for nine months declined 26.9% yr/yr

  • Company advances Australian oncology trial and Long COVID research

Outlook

  • Company continues research on Hemopurifier for broader clinical applications

  • Aethlon advances Long COVID research with Hemopurifier targeting EVs

  • Company remains committed to advancing clinical programs with operational discipline

Result Drivers

  • QUARTERLY EXPENSES - Rose 13.6% yr/yr, primarily driven by higher payroll and related costs

  • COST EFFICIENCY - Year-to-date operating expenses declined 26.9% due to disciplined cost controls

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Operating Expenses

$2.06 mln

Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

  • Wall Street's median 12-month price target for Aethlon Medical Inc is $12.38, about 492.1% above its February 11 closing price of $2.09

Press Release: ID:nPn1qKRy8a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment